Healthcare provider profile · identity verified

Dennis Vu, DO

Family Practice · RIVERSIDE, CA · NPI 1922175744

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	1061	370
Lisinopril	Lisinopril	546	180
Amlodipine Besylate	Amlodipine Besylate	291	103
Levothyroxine Sodium	Levothyroxine Sodium	261	83
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	258	52
Rosuvastatin Calcium	Rosuvastatin Calcium	254	86
Metformin Hcl Er	Metformin Hcl	215	106
Losartan Potassium	Losartan Potassium	211	78
Glipizide	Glipizide	180	64
Terazosin Hcl	Terazosin Hcl	180	58
Metformin Hcl	Metformin Hcl	177	62
Alendronate Sodium	Alendronate Sodium	174	67
Omeprazole	Omeprazole	160	71
Pradaxa	Dabigatran Etexilate Mesylate	139	33
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	122	45
Metoprolol Tartrate	Metoprolol Tartrate	113	43
Hydrochlorothiazide	Hydrochlorothiazide	109	39
Atenolol	Atenolol	99	32
Simvastatin	Simvastatin	96	30
Pioglitazone Hcl	Pioglitazone Hcl	95	34
Pantoprazole Sodium	Pantoprazole Sodium	91	29
Albuterol Sulfate Hfa	Albuterol Sulfate	87	40
Allopurinol	Allopurinol	80	24
Meloxicam	Meloxicam	73	38
Bisoprolol Fumarate	Bisoprolol Fumarate	72	31
Furosemide	Furosemide	72	27
Potassium Chloride	Potassium Chloride	61	28
Humulin N	Insulin Nph Human Isophane	59	18
Gabapentin	Gabapentin	53	21
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	50	23
Carvedilol	Carvedilol	46	16
Fluoxetine Hcl	Fluoxetine Hcl	46	21
Spiriva Respimat	Tiotropium Bromide	46	12
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	46	15
Tamsulosin Hcl	Tamsulosin Hcl	45	19
Cephalexin	Cephalexin	43	36
Humulin N Kwikpen	Insulin Nph Human Isophane	41	12
Hydralazine Hcl	Hydralazine Hcl	41	12
Jardiance	Empagliflozin	40	17
Finasteride	Finasteride	35	15
Triamcinolone Acetonide	Triamcinolone Acetonide	34	20
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	33	33
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	32	13
Famotidine	Famotidine	31	17
Naloxone Hcl	Naloxone Hcl	31	28
Ondansetron Odt	Ondansetron	31	suppressed
Acyclovir	Acyclovir	29	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	29	12
Arexvy	Rsvpref3 Antigen/As01e/Pf	28	28
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	28	suppressed
Tramadol Hcl	Tramadol Hcl	28	suppressed
Veo Insulin Syringe	Syringe And Needle,insulin,1ml	27	suppressed
Hydrocortisone	Hydrocortisone	26	suppressed
Breyna	Budesonide/Formoterol Fumarate	24	13
Clopidogrel	Clopidogrel Bisulfate	22	suppressed
Trazodone Hcl	Trazodone Hcl	22	suppressed
Testosterone	Testosterone	21	suppressed
Morphine Sulfate Er	Morphine Sulfate	20	suppressed
Spironolactone	Spironolactone	20	suppressed
Citalopram Hbr	Citalopram Hydrobromide	19	suppressed
Dexamethasone	Dexamethasone	18	11
Eliquis	Apixaban	18	suppressed
Levetiracetam	Levetiracetam	18	suppressed
Alvesco	Ciclesonide	17	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	17	17
Varenicline Tartrate	Varenicline Tartrate	17	suppressed
Digoxin	Digoxin	16	suppressed
Ibuprofen	Ibuprofen	16	suppressed
Montelukast Sodium	Montelukast Sodium	16	suppressed
Baclofen	Baclofen	15	suppressed
Ozempic	Semaglutide	15	suppressed
Tradjenta	Linagliptin	15	suppressed
Chlorthalidone	Chlorthalidone	14	suppressed
Clonazepam	Clonazepam	14	suppressed
Xarelto	Rivaroxaban	14	suppressed
Metronidazole	Metronidazole	13	suppressed
Sertraline Hcl	Sertraline Hcl	13	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	12	suppressed
Dabigatran Etexilate	Dabigatran Etexilate Mesylate	12	12
Fentanyl	Fentanyl	12	suppressed
Terbinafine Hcl	Terbinafine Hcl	12	suppressed
Propranolol Hcl	Propranolol Hcl	11	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error